I'm afraid about receiving my first treatment - any advice?

 

Q: I'm afraid about receiving my first treatment--any advice? 

A: It's normal to be anxious about your first chemotherapy or radiation therapy treatment. It's likely you've never experienced this treatment before. You probably have heard other peoples' stories about these treatments. Remember, this is your unique experience.

Even if you're well-informed about possible side effects from your prechemotherapy or radiation therapy teaching, you don't know how you will react specifically. You are taking control of your situation by starting treatment. You are now on the road to getting rid of the cancer. This is a very positive step. Most patients, after being initially scared and anxious, feel fine after their first treatment session. Now you'll know what to anticipate with the next treatment. You will also better know the nurses caring for you.

Our purpose is to promote the health of your mind, body, and spirit as you journey through this treatment. Your nurses recognize that this first treatment is your most difficult. We give you extra time on this important day so we can answer all your questions and provide the emotional support you need. There isn't anything you can't ask us and there isn't any emotion that we haven't experienced with our patients and their families. As you move into active treatment, you'll feel a sense of accomplishment and gaining control. That also helps you get through the first session.
--Bernice Crook, RN, OCN

You can reduce your anxiety about starting treatment by taking an active role.

Latest Cancer News
ACOG Updates Cervical Cancer Screening Guidelines

November 20, 2009 — The American College of Obstetricians and Gynecologists (ACOG) has revised its cervical cancer screening recommendations: the organization now recommends that women begin screening at the age of 21 and receive screening at less frequent intervals. These recommendations will be published in the December 2009 issue of Obstetrics and Gynecology.

New Velcade®-melphalan Transplant Regimen for Multiple Myeloma

November 20, 2009 — Researchers from France have reported encouraging results with adding Velcade® (bortezomib) to high-dose melphalan followed by autologus stem cell infusion for initial treatment of patients with newly diagnosed multiple myeloma. The details of this Phase II study appeared in an early online publication in Blood on November 2, 2009.

Folic Acid May Be Beneficial in Patients with Recurrent Colorectal Adenoma Who Are Folate Deficient

November 20, 2009 — Researchers affiliated with the Health Professional Follow-Up Study and the Nurses’ Health Study have reported that folic acid supplementation in patients with recurrent colorectal adenoma was not protective or harmful in most patients. However, patients who were folate deficient had a significant 39% decrease in adenoma recurrence. The details of this study appeared in an early online publication on October 28, 2009 in the American Journal of Clinical Nutrition.

Select news items provided by Reuters Health